Author: Ravi Shankar

• FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic alterations (AGAs) following progression on immune checkpoint inhibitor (ICI) and chemotherapy.
• BeyondSpring enters into a strategic transaction to sell its majority equity interest in its Chinese subsidiary to an investor who will fund the China portion of the Phase 3 DUBLIN-4 trial, which is expected to represent approximately 50% of the planned global enrollment of 442 patients.
• This non-dilutive transaction provides a financially efficient path toward the next major clinical milestone for Plinabulin, which is DUBLIN-4 interim analysis of 221 Progression-Free Survival (PFS) events.
• Management will host a conference call and webcast today at 8:00 a.m. ET to discuss these developments.

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) without actionable genomic alterations (AGAs) whose disease has progressed following prior anti-PD-(L)1 antibody therapy and platinum-based chemotherapy, representing patients in the second- or third-line treatment setting. This is the patient population being studied in BeyondSpring’s global Phase 3 DUBLIN-4 trial.

Plinabulin, a first-in-class small molecule agent, has an extensive clinical safety database with more than 700 cancer patients. Its differentiated immuno-modulating mechanism and previously reported encouraging clinical data from DUBLIN-3 and Study 303 support the trial design of DUBLIN-4 in Plinabulin mechanism-targeted post-ICI non-squamous NSCLC patients.

The Company also announced a strategic transaction with Biolin Investment Limited (“Biolin”) relating to the China portion of DUBLIN-4. Under the arrangement, the Company will sell its majority equity interest in its Chinese subsidiary, and Biolin will support DUBLIN-4 clinical development activities in China, which activities are expected to include enrollment of approximately 221 patients. BeyondSpring expects the transaction to substantially reduce its cash requirements for DUBLIN-4 while supporting efficient enrollment and the generation of China clinical data for the global trial.

“We believe the FDA Fast Track designation, an FDA-aligned global Phase 3 strategy, and funding to support China-generated clinical data would meaningfully strengthen our ability to advance Plinabulin and DUBLIN-4 toward the trial’s next major clinical milestone—the prespecified interim analysis at 221 PFS events,” said Min Qiu, CEO of BeyondSpring. “Fast Track designation underscores the significant unmet medical need for the DUBLIN-4 patient population in NSCLC patients whose disease has progressed following ICI and without AGAs, with limited options and docetaxel as the standard of care. Importantly, the strategic transaction provides a time- and capital-efficient approach to executing our global Phase 3 clinical strategy. Positive results from the interim analysis could represent a meaningful value inflection point for BeyondSpring.”

FDA Fast Track Designation

FDA Fast Track designation is designed to facilitate development and expedite review of therapies intended to treat serious conditions with unmet medical needs. The designation provides opportunities for more frequent interactions with the FDA regarding the development program and may allow for rolling review of a future regulatory application. Plinabulin may also be eligible for Priority Review if applicable criteria are met.

DUBLIN-4: Global Registrational Phase 3 Strategy

DUBLIN-4 is a randomized global Phase 3 trial evaluating Plinabulin plus docetaxel versus docetaxel alone in patients with advanced non-squamous NSCLC without actionable genomic alterations following progression on ICI and chemotherapy.

Approximately 442 patients are planned to be randomized 1:1, with overall survival (“OS”) as the primary endpoint and PFS and objective response rate (“ORR”) as secondary endpoints. The trial includes a prespecified interim analysis at 221 PFS events.

Approximately half of the planned trial population is expected to be enrolled at participating sites in China under the strategic arrangement, with the remainder expected to be enrolled through the broader global DUBLIN-4 program, including in the United States and other regions. BeyondSpring intends for data generated across participating regions to form part of an integrated global clinical dataset supporting its registration strategy for Plinabulin.

Strategic Arrangement Supports Global Phase 3 Execution

BeyondSpring has entered into a definitive agreement with Dalian Wanchunbulin Pharmaceuticals Ltd., the Company’s Chinese subsidiary (“Bulin”), and Biolin, pursuant to which BeyondSpring will sell BeyondSpring Ltd., its wholly owned subsidiary that indirectly holds the majority equity interest in Bulin, to Biolin.

Under the arrangement, Biolin will support the funding of clinical development activities conducted by Bulin at participating sites in China, and BeyondSpring will receive access to clinical data generated from the China portion of DUBLIN-4. Patients enrolled in China are expected to represent approximately half of the planned 442-patient global enrollment. Biolin’s obligation to support the funding of the China portion of DUBLIN-4, and to cause Bulin to conduct and use commercially reasonable efforts to complete the trial and perform certain related activities, will constitute the non-cash consideration for the sale of BeyondSpring Ltd.

Following the transaction, BeyondSpring will retain global rights to Plinabulin outside Greater China. The arrangement is expected to substantially reduce BeyondSpring’s cash requirements associated with DUBLIN-4, while China’s large eligible NSCLC patient population is expected to support efficient enrollment.

Conference Call and Webcast Information

BeyondSpring’s management will host a conference call and webcast today at 8:00 a.m. Eastern Time to discuss the announcement. The dial-in numbers are 1-877-737-7051 (U.S.) or 1-201-689-8878 (international). The live webcast will be available here. An archived replay of the webcast will be available following the presentation on BeyondSpring’s website www.beyondspringpharma.com under “Events” in the Investor section.

About Plinabulin and the Clinical Rationale for DUBLIN-4 Trial

Plinabulin is a late-stage, first-in-class investigational GEF-H1 agonist with a differentiated mechanism of action that includes dendritic cell maturation, anti-angiogenic activity and mitigation of chemotherapy-induced neutropenia. To date, more than 700 cancer patients have been treated with Plinabulin across multiple clinical programs in various cancer types, demonstrating an extensive clinical safety database.

The post-ICI setting remains difficult to treat, with 12 Phase 3 trials evaluating different treatment approaches against docetaxel, including four involving ADCs, having failed to demonstrate an overall survival benefit over docetaxel.

In the Phase 3 DUBLIN-3 Trial, published in The Lancet Respiratory Medicine in 2024, Plinabulin combined with docetaxel demonstrated a statistically significant improvement in OS in second- and third-line EGFR wild-type NSCLC vs. docetaxel alone (n=559), showing superior OS benefit in non-squamous patients (n=332, OS HR 0.72, p=0.0078). The combination also demonstrated statistically significant improvements compared to docetaxel alone, including doubling 2-year and 3-year survival rates and improvements in PFS and ORR, while also significantly reducing grade 4 neutropenia (p<0.0001).

Importantly, a post hoc analysis of the DUBLIN-3 post-ICI subgroup showed a median OS of 15.8 months with Plinabulin plus docetaxel versus 11.7 months with docetaxel alone (HR 0.55), with ORR of 18.2% versus 8.0%, respectively. These findings support the clinical rationale for Plinabulin’s differentiated dendritic cell maturation mechanism and its further evaluation in DUBLIN-4.

This rationale was further supported by prospective data from the Phase 2 Study 303 (n=47), presented at ASCO 2026. In patients with NSCLC whose disease had progressed following PD-1 inhibitor treatment, the combination of Plinabulin, docetaxel and a PD-1 inhibitor demonstrated encouraging anticancer activity. With a median follow-up of 28.8 months, the Plinabulin combination showed a median PFS of 7.0 months, a disease control rate of 79.5%, and a confirmed ORR of 18.2%, with a 2-year OS rate of 58%, nearly double the historical rate reported with docetaxel in a similar patient population.

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet needs. Its lead asset, Plinabulin, has been studied in more than 700 cancer patients and is in late-stage development across multiple cancer indications. Plinabulin’s novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anticancer activity and immune modulation, offering a unique approach to resensitizing tumors that have progressed on checkpoint inhibitors. In addition, it has the potential to synergize with chemotherapy, antibody-drug conjugates (ADCs), radiation, and checkpoint inhibitors. BeyondSpring is also an early incubator of and maintains an equity interest in SEED Therapeutics, a clinical-stage targeted protein degradation molecular glue company with investments from Eli Lilly and Eisai. Learn more at beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, the risk that the conditions to the closing of the transaction may not be satisfied or waived on the expected timeline or at all; the inability of Biolin and Bulin to perform their respective funding, clinical development, data generation and other obligations under the definitive agreement; delays or challenges in enrollment or execution of the China portion of DUBLIN-4; regulatory, data-transfer or human-genetic-resources requirements that may affect the transfer or use of China-generated clinical data; the inability of such data to support regulatory submissions outside Greater China; the possibility that the transaction may not achieve the anticipated financial, operational or strategic benefits; difficulties in raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the possibility that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company’s expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company’s product candidates; increased competition in the market; the possibility that Fast Track designation may not result in a faster development or regulatory review process or otherwise provide the anticipated benefits, and the fact that such designation does not increase the likelihood of regulatory approval; the Company’s ability to meet the continued listing requirements of The Nasdaq Stock Market LLC; and other risks described in BeyondSpring’s most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: B76) is pleased to announce the recommencement of diamond drilling at the Coyote target on its flagship Moonlite Project in the Athabasca Basin, Saskatchewan, part of the southwestern Athabasca Basin Joint Venture (“JV”) with Atha Energy Corp. (“Atha Energy”) (TSX-V: SASK).

Matthew Schwab, CEO of Stallion Uranium, said, “Getting the drills turning again at Coyote allows us to immediately build on everything we learned during the first phase of the program. We now have a significantly stronger understanding of the geology, structure and radiometric response of the system, and that knowledge has directly influenced our Phase II targeting.

“With approximately 2,165 metres remaining, our focus is straightforward: deploy those metres into the highest-priority areas identified by our technical team. We believe the integration of drilling, geophysics and structural interpretation has given us our clearest picture of Coyote to date and provides a strong foundation for this next phase of drilling.”

Drilling crews have remobilized to Coyote to begin Phase II of Stallion’s expanded 2026 drilling campaign. The Company has completed approximately 4,585 metres of the planned 6,750-metre program, leaving approximately 2,165 metres of drilling to be completed during the current phase.

Phase II will build directly on the geological, structural and radiometric information generated during the first phase of drilling and will continue testing priority areas along the Coyote corridor.

Phase II Drilling:

The 2026 program represents the first systematic drill testing of the Coyote target and has provided Stallion with a significantly improved understanding of the geology and structural architecture underlying the corridor.

SRK Consulting has completed a regional-scale Structural Interpretation and Targeting Assessment designed to identify the primary and secondary structural controls associated with uranium mineralization in the western Athabasca Basin. The assessment provides Stallion with an additional framework for interpreting potential structural conduits and traps at Coyote and has been incorporated into the Company’s Phase II targeting.

Information collected from drilling completed to date has been integrated with Stallion’s geological interpretation, structural analysis and expanding geophysical dataset to refine the Company’s Phase II drill targets. The remaining approximately 2,165 metres of drilling will focus on the highest-priority areas identified through this integrated targeting approach.

Figure 1: Current drilling progress at the Moonlite Project

Stallion intends to use the remaining 2026 drilling to continue evaluating the geological and structural controls encountered during the program while testing additional high-priority positions within the Coyote system.

Advancing Coyote Through an Expanding Dataset:

Stallion began 2026 with an initial 4,000-metre drilling program at Coyote. As drilling progressed and additional geological and geophysical information became available, the program was first expanded to 5,500 metres and subsequently to approximately 6,750 metres.

Rather than simply adding metres to the original drill plan, the expanded program has allowed Stallion’s technical team to continuously refine subsequent drill locations as new information has been generated.

The commencement of Phase II represents the next stage of that process, with the remaining holes incorporating the Company’s most complete geological and geophysical interpretation of Coyote to date.

Figure 2: Priority target areas identified across the Moonlite Project

Importantly, the knowledge developed through drilling at Coyote is also contributing to Stallion’s evaluation and prioritization of additional target areas across the broader Moonlite Project.

2026 Moonlite Program – Next Steps:

With drilling now recommenced, Stallion’s near-term activities at Moonlite will focus on:

• Completing approximately 2,165 metres of additional drilling as part of the expanded 6,750-metre 2026 Coyote program;
• Testing refined Phase II targets developed from the integration of drilling, geological interpretation and geophysical datasets;
• Continuing geological logging, downhole gamma probing, sampling and interpretation of drill core from the 2026 program;
• Incorporating new Phase II results into the evolving geological and structural model for Coyote; and

The Company will provide additional updates as Phase II drilling progresses and results become available.

Gamma Logging and Geochemical Assaying:

All core radioactivity is measured using an RS-125 Super-SPEC Handheld Gamma-Ray Spectrometer. Downhole radiometric surveying is conducted using a Mount Sopris QL40GR-1000 downhole total gamma probe.

Drill core samples from the 2026 program are shipped to the Saskatchewan Research Council Geoanalytical Laboratories (“SRC”) in Saskatoon, Saskatchewan, an ISO/IEC 17025 accredited analytical laboratory. Stallion requests multi-element analysis by ICP-MS and ICP-OES using total and partial digestion, with boron analyzed by fusion. One half of the split core is retained and the other half is submitted to SRC for analysis.

Blanks, standard reference materials and repeats are inserted into the sample stream at regular intervals by Stallion Uranium geologists and SRC in accordance with industry-standard quality assurance/quality control (“QA/QC”) procedures.

The reader is cautioned that gamma probe readings are not directly or uniformly related to uranium grades of the rock measured and should be used only as a preliminary indication of the presence of radioactive materials.

Upcoming Events:

On Saturday, October 17, at 11:45 a.m. MDT, CEO Matthew Schwab will present at the Schachter Catch the Energy Conference in Calgary, Alberta, providing an update on the Company’s 2026 exploration activities and discussing its ongoing exploration strategy. Further information can be found here.

Qualifying Statement:

The foregoing scientific and technical disclosures for Stallion Uranium have been reviewed and approved by Darren Slugoski, P.Geo., VP Exploration, a registered member of the Professional Engineers and Geoscientists of Saskatchewan. Mr. Slugoski is a Qualified Person as defined by National Instrument 43-101.

About Stallion Uranium Corp.:

Stallion Uranium is working to ‘Fuel the Future with Uranium’ through the exploration of roughly 1,700 sq/km in the Athabasca Basin, home to the largest high-grade uranium deposits in the world. The Company, with JV partner Atha Energy, holds a significant contiguous project in the western Athabasca Basin adjacent to multiple high-grade discovery zones. With a commitment to responsible exploration and cutting-edge technology such as the use of the proprietary Haystack TI technology, Stallion is positioned to play a key role in the future of clean energy.

Our leadership and advisory teams are comprised of uranium and precious metals exploration experts with the capital markets experience and the technical talent for acquiring and exploring early-stage properties. For more information visit stallionuranium.com.

On Behalf of the Board of Stallion Uranium Corp.:

Matthew Schwab
CEO and Director

Corporate Office:
700 – 838 West Hastings Street,
Vancouver, British Columbia,
V6C 0A6

T: 604-551-2360
info@stallionuranium.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to the Company’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this material change report should not be unduly relied upon. These statements speak only as of the date they are made.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/432526aa-b950-4eaa-b442-d51dda5d7863

https://www.globenewswire.com/NewsRoom/AttachmentNg/9127718a-1e31-4f8a-a093-d72ff9a2d394

Estimates secured in due diligence provided information of 2.9 million barrels of oil reserves plus an estimated $100 million in natural gas to be utilized for Alpha Compute’s Data Center with over 200 MW of behind-the-meter power generation

Pittsburgh, PA, Sept. 29, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (Nasdaq: ALP) (“Alpha Compute” or the “Company”), a vertically integrated technology pioneer in Sovereign Intelligence, Confidential Compute and GPU-as-a-service (GPUaaS), today announced an update on the Alpha Energy 02 transaction, first announced on September 22, 2026 with a total purchase price is USD $5.5 million.

Last week, Alpha Compute’s oil, gas, and minerals leadership visited the property to review additional due diligence documents, met with the sellers/managers, and toured the pad sites. Information on the operations, financials,  on-site verification of well resources, and equipment inventory were obtained and completed. 

Evaluation of log files from one natural gas test well into the Marcellus shale indicates substantial recoverable gas resources across multiple formations linked to the acquired land and mineral rights. Supplemented by potential unconstrained production-type curves from adjacent analog wells of two producing shallow gas wells, these reserves correspond to an estimated 200 MW of power generation capacity dedicated to Alpha Compute data center planned for Q1 2028. Beyond providing on-site, behind-the-meter power for planned data center developments, the transaction encompasses over 75 active oil wells with an estimated 2.9 million barrels of remaining oil-in-place.

Update On Assets

The acquisition delivers a stacked-resource position on more than 300 acres of surface, mineral and gas rights spanning both the Marcellus and Utica shale formations. The assets include:

• One natural gas test-well with proven natural gas reserves;
• More than 75 existing, producing oil and shallow gas wells with complete pump jack inventories;
• Operational maintenance facilities, heavy equipment and associated gathering infrastructure; and
• Full surface control, enabling co-location of power generation and compute on the same parcel.

Oil in Place and Illustrative Asset Value

Historical documentation and test-well logs obtained in due diligence from an assessment estimates approximately 10,000 barrels per acre of light Pennsylvania-grade sweet crude oil across the subsurface parcels, implying roughly 3.0 million barrels of original oil in place across the acquired acreage. Preliminary evaluations indicate that only an estimated 4% of that volume has been extracted to date, leaving approximately 2.9 million barrels of oil in place.

For context, at prevailing West Texas Intermediate prices of roughly $90 per barrel in late September 2026, the remaining in-place volume carries an illustrative gross, undiscounted value on the order of $260 million. 

Based on standard primary-recovery rates of 5% to 15% for shallow Appalachian crude, estimated recoverable reserves range from 145,000 to 435,000 barrels. At current market rates, this projects to roughly $13 million to $39.1 million in gross top-line revenue, prior to royalties, taxes, and operational expenses. Backed by more than One decades of documented financial history, the current wells remain active and cash-flow positive today. A planned workover capital expenditure of approximately $3.5 million is projected to restore field output to these higher historical rates. 

Marcellus and Utica Gas Potential

One test-well is the near-term catalyst. Horizontal wells completed in the Pennsylvania Marcellus and Utica typically recover on the order of 10 to 20 billion cubic feet (Bcf) of natural gas each over their producing lives, implying combined estimated ultimate recovery of approximately 20 to 40 Bcf for the One wells, depending on lateral length, completion design and reservoir quality. Bringing both wells online is expected to cost approximately $10 million to $12 million per well.

At an illustrative realized price of $2.00 to $2.50 per MMBtu, reflecting Henry Hub pricing of roughly $3.00 less Appalachian basis differentials, the One wells alone represent approximately $40 million to $100 million of gross lifetime gas revenue if sold to market. Across the full 300-acre block, the stacked Marcellus and Utica formations are estimated to hold roughly 50 to 70 Bcf of recoverable gas, supporting additional drilling locations beyond the One existing wells.

Alpha Compute does not intend to simply sell this gas. Consumed on site through simple-cycle generation at approximately 7.5 MMBtu per megawatt-hour, initial combined production of 20 to 40 million cubic feet per day from the One wells could support roughly 100 to 200 MW of generation capacity at first production, with the combined 20 to 40 Bcf of recoverable gas sufficient to sustain approximately 30 to 60 MW of continuous load for a decade. This converts a commodity exposed to Appalachian basis discounts into low-cost, dispatchable power for AI compute.

“We paid $5.5 million for an operating business that produces oil and cash flow today, and that sits on roughly 2.9 million barrels of oil in place and one gas well ready to complete,” said Enzo Villani, Executive Chairman and President of Alpha Compute Corp. “Our updated geological work, modern appraisals and third-party reserve engineering are underway, and we expect them to support a substantial revaluation of these assets on our balance sheet. In the meantime, the site pays for itself.”

“This acquisition gives Alpha Compute something few AI infrastructure companies have: the fuel, the land and the compute on a single asset,” said Brittany Kaiser, CEO of Alpha Compute Corp. “With one well already drilled. Completing them is the fastest path in Pennsylvania to behind-the-meter power for our next data center, and we will do it under Pennsylvania DEP oversight, in partnership with the county and with the local community at the forefront of our plans.”

Next Steps

• Complete updated geological assessments, modern appraisals and independent reserve engineering to map recoverable oil and gas volumes;
• Advance DEP permitting and contracting for the hydraulic fracturing and completion of the One gas wells;
• Finalize the design of on-site generation and the planned data center, replicating the community-first framework developed for Alpha Compute’s Northern Pennsylvania site; and
• Enter binding covenants with local and county governments aligned with municipal development goals.

Facility Design and Environmental Compliance

Development will comply fully with local county ordinances and land-use regulations, regional grid policies and interconnection standards, and Pennsylvania Department of Environmental Protection (DEP) regulations, including applicable operator registration, bonding and well-plugging requirements.

Community Partnership and Economic Impact

• Job Creation: Projected creation of skilled permanent and construction positions;
• Infrastructure Investment: Modernization of site utilities and sustainable integration with local energy grid capacity;
• Environmental Stewardship: Post-closing environmental compliance, plugging assurances and responsible well management under DEP oversight.

Summary of Illustrative Estimates

Metric	Basis	Illustrative Estimate
Original oil in place (historical Halliburton assessment)	~10,000 bbl/acre × ~300 acres	~3.0 million barrels
Oil extracted to date (preliminary)	~4% of estimated in-place volume	~120,000 barrels
Remaining oil in place	In-place, not recovered volume	~2.9 million barrels
Illustrative gross value of remaining oil in place	WTI ~$90/bbl (late Sept. 2026); Penn Grade crude priced near WTI	~$260 million (undiscounted, in-place)
Illustrative recoverable oil (primary recovery)	5-15% of remaining in-place volume	~145,000–435,000 barrels (~$13M–$39.1M gross at ~$90/bbl)
One test-drilled, uncompleted gas wells – estimated ultimate recovery	Typical PA Marcellus/Utica horizontal well: ~10–20 Bcf each	~20–40 Bcf combined
Illustrative gross gas revenue, One wells (life of well)	Realized ~$2.00–$2.50/MMBtu (Henry Hub ~$3.00 less Appalachian basis)	~$40M–$100M (undiscounted)
Estimated completion cost to bring the one well online	Industry range for Appalachian horizontal completions	~$10M–$12M per well
Behind-the-meter generation potential, One test well	Initial ~20–40 MMcf/d combined; ~7.5 MMBtu per MWh simple-cycle	~100–200 MW initially; ~30–60 MW sustained over 10 years Plus access to major gas lines on property.
Recoverable gas across the ~300-acre block (both formations)	~0.08–0.12 Bcf/acre per formation, Marcellus + Utica	~50–70 Bcf

All figures above are illustrative, order-of-magnitude estimates prepared by the Company from historical third-party documentation, publicly available basin-level type curves and prevailing commodity prices as of late September 2026. They are not estimates of proved, probable or possible reserves as defined by the U.S. Securities and Exchange Commission, have not been prepared or reviewed by an independent petroleum engineer, are undiscounted, and are stated before royalties, operating costs, capital costs and taxes. Actual results will depend on completed reserve engineering, well performance, commodity prices, permitting and financing. See “Forward-Looking Statements.”

About Alpha Compute Corp.

Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute. Alpha Compute’s mission is to support clients, subsidiaries, and partners across critical sectors including: finance, defense, intelligence, and media with the essential framework for any organization requiring secure, confidential computing environments. 

Alpha Compute Corp is domiciled in the British Virgin Islands with offices in New York, Los Angeles, Miami, Amsterdam and Toronto. Alpha Compute is a founding partner of the Right2Compute Coalition.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements.

Forward-looking statements in this release include, without limitation: estimates of oil and gas in place, recoverable volumes, estimated ultimate recovery, completion costs, commodity prices, realized prices, gross revenue and generation capacity; the anticipated revaluation of the acquired assets; the completion and performance of the one drilled gas wells; title, acreage and net revenue interest; the development, permitting, financing, construction and commercial operation of on-site generation and the planned data center; and potential economic, environmental and community impacts.

These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the results of updated geological assessments, appraisals and independent reserve engineering; well performance and recovery factors; volatility in oil and natural gas prices and Appalachian basis differentials; permitting, environmental and well-plugging risks; the timing and progress of the Company’s strategic initiatives; reliance on third-party vendors and partners; the ability to secure additional financing; uncertainty around the Company’s investments and legacy business; risks related to technology platforms and ecosystems; and general market and economic conditions. A more complete discussion of these risks is set forth under “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2026, as amended.

Undue reliance should not be placed on these forward-looking statements. The forward-looking statements contained herein are made as of the date of this press release, and the Company undertakes no obligation to update or revise them publicly, except as required by law.

Investor & Media Contact

Alpha Compute Corp.
ir@alphacompute.ai
www.alphacompute.ai

CONTACT: ir(at)alphacompute.ai

• OKYO demonstrates continued commitment to optometry and ophthalmology

LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026
New Orleans, Louisiana

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases
Presentation Date/Time: Thursday, October 8, 2026, 1:29 PM CT
Breakout: Anterior Segment, Room 243-245
Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma
Moderators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD

American Academy of Optometry takes place September 30 – October 1 in Anaheim where the leadership team will engage leading optometric experts.

American Academy of Ophthalmology takes place October 9-12 in New Orleans where the leadership team will engage with leading ophthalmology experts.

The Company’s continued presence at leading ophthalmic meetings supports its commitment to engaging both optometrists and ophthalmologists, who both play a role in the diagnosis and care of patients with neuropathic corneal pain (NCP).

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

USD $150,000 engagement to expand REV’s investor awareness across the United States.

New REV Video: Why Helium Matters
https://youtu.be/V8IOCW8YyBo

KELOWNA, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) — REV Exploration Corp. (“REV” or the “Company”) (TSXV: REVX; OTCID: REVFF; FSE: 7FF) is pleased to announce that it has entered into a consulting agreement (the “Agreement”) with RazorPitch Inc. (“RazorPitch”) to provide investor marketing and public relations services in compliance with the policies and guidelines of the TSX Venture Exchange (the “TSXV”) and other applicable securities legislation.

Marketing/Investor Relations Agreement

RazorPitch is a capital markets advisory and communications firm whose principal is Jason Hilton. RazorPitch’s business address is 9215 Belleza Way #204, Fort Myers, Florida, 33908, USA, and the firm can be contacted at jason@razorpitch.com.

Neither RazorPitch nor its principals currently own any securities of the Company; however, they may purchase securities of the Company from time to time for investment purposes. RazorPitch and its principals are at arm’s length to the Company.

Under the Agreement, RazorPitch will provide digital marketing, social media, content creation, and investor and broker outreach, together with related consulting on strategic business planning, press-release preparation and shareholder communications.

The Agreement has a term of nine (9) weeks (October 5, 2026 to December 5, 2026) and provides for a cash fee of USD $150,000 payable in a single installment from the Company’s working capital. The Agreement, including the Company’s obligation to commence services and make payment thereunder, is subject to approval of the TSXV.

Mr. Jordan Potts, REV CEO, commented: “Strengthening our presence with investors across the United States is an important next step as we accelerate REV’s Helium-focused portfolio in the Northern Great Plains with initial drilling. RazorPitch’s experience in capital markets communications will help ensure our story reaches a broader base of American investors.”

About REV Exploration Corp.

REV is a mineral exploration company with a diversified portfolio of strategic mining assets, together with meaningful and growing exposure to the Helium and Natural Hydrogen sectors focused on America’s Northern Great Plains and southernmost Alberta along the Montana border. The Company owns oil and gas leasehold interests in Montana covering approximately 10,600 acres, in addition to a series of PNG leases in Alberta along the Alberta–Montana border, including the Aden Dome Project. REV also owns 6 million shares of MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF) and 12.4 million shares of Major Gold Corp., a private company that is pursuing a listing on the TSX Venture Exchange.

For further information on the Company, readers are referred to the Company’s website at REVexploration.com and its Canadian regulatory filings on SEDAR+ at sedarplus.ca.

Figure 1: Savanna Drill Rig #416 at Aden Dome as Inaugural Drilling Commences

REV Exploration Corp.
Unit 220 – 1060 Manhattan Dr.
Kelowna, BC V1Y 9X9
Tel: 604-682-7970
info@revexploration.com
REVexploration.com

Jordan Potts, CEO and Director

For further information, please contact:
Chad Levesque
Investor Relations
1-306-981-4753
info@revexploration.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information in this release includes, but is not limited to, statements regarding the drilling of the Aden Well, including its planned total depth, target intervals and formation evaluation program; the timing of laboratory analysis and the reporting of results; the permitting and drilling of wells at West Butte; the advancement, prioritization and evaluation of exploration prospects; the geological potential of the Company’s properties, including for Helium and Natural Hydrogen; the proposed listing of Major Gold Corp. on the TSX Venture Exchange; and the Company’s future business strategy and objectives.

Forward-looking information is based on management’s expectations and reasonable assumptions as of the date of this news release, including, without limitation, assumptions regarding the availability of drilling equipment, technical personnel and service providers; operating and weather conditions; the accuracy and reliability of geological, geophysical and other technical information; the Company’s ability to obtain required permits and financing on reasonable terms if required; and general economic, market and business conditions.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, without limitation, risks relating to mineral and natural gas exploration and development, including the risk that exploration or drilling results may not confirm geological interpretations or expectations; risks inherent in drilling operations, including mechanical failure, hole instability, cost overruns, delays and accidents; the risk that the Aden Well may not reach its planned total depth or may not encounter reservoir, Helium or Natural Hydrogen in any target interval; the risk that gas indications may not be confirmed by laboratory analysis or testing; the speculative nature of early-stage exploration properties; permitting, land tenure, environmental compliance, regulatory and community relations risks; commodity price volatility; fluctuations in currency exchange rates; access to capital; dilution; reliance on key personnel, third-party consultants and contractors; and general economic, market, political and social uncertainties. Investors should review the risk factors and other disclosure contained in the Company’s public filings available under its profile on SEDAR+.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this news release, and the Company does not undertake any obligation to update or revise such information except as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2d1559e-7f03-4ea5-85ed-c5ae52b1bca9

BEIJING, Sept. 29, 2026 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced the appointment of Mr. Philip Yifei Bao to its board of directors (the “Board”), effective September 29, 2026. Following Mr. Bao’s appointment, the Board consists of ten directors, including three independent directors.

“We are pleased to welcome Mr. Bao to our Board,” said Mr. Hui Li, Chairman of the Board of Luckin Coffee. “His extensive experience investing in consumer businesses, deep knowledge of the China market and broad global perspective will bring valuable insights to the Board. We look forward to working closely with him as Luckin Coffee continues to execute its long-term growth strategy and create sustainable value for its shareholders.”

Mr. Bao is the Director of Private Equity China within the Private Equity platform of Mubadala Investment Company P.J.S.C. (“Mubadala”), where he leads Mubadala’s private equity investments in China. He is based in Beijing. Prior to joining Mubadala, Mr. Bao worked in private equity and investment banking in London from 2011 to 2017. Mr. Bao holds Bachelor of Arts and Master of Engineering (Hons) degrees in Electrical and Electronic Engineering from Gonville and Caius College, University of Cambridge.

SAFE HARBOR STATEMENTS

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. Luckin Coffee may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Luckin Coffee’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the expense, timing and outcome of existing or future legal and governmental proceedings or investigations in connection with Luckin Coffee; the outcome and effect of the restructuring of Luckin Coffee’s financial obligations; Luckin Coffee’s growth strategies; its future business development, results of operations and financial condition; the effect of the non-reliance identified in, and the resultant restatement of, certain of Luckin Coffee’s previously issued financial results; the effectiveness of its internal control; its ability to retain and attract its customers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with its suppliers and business partners; trends and competition in the coffee industry or the food and beverage sector in general; changes in its revenues and certain cost or expense items; the expected growth of China’s coffee industry or China’s food and beverage sector in general; governmental policies and regulations relating to Luckin Coffee’s industry; and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in Luckin Coffee’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Luckin Coffee undertakes no obligation to update any forward-looking statement, except as required under applicable law.

ABOUT LUCKIN COFFEE INC.

Luckin Coffee Inc. (OTC: LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. Empowered by proprietary technologies, Luckin Coffee pursues its vision to build a world-class coffee brand and become a part of everyone’s daily life. Luckin Coffee was founded in 2017 and is based in China. For more information, please visit investor.lkcoffee.com.

INVESTOR AND MEDIA CONTACTS

Investor Relations Contact
Luckin Coffee IR
Email: ir@lkcoffee.com

Bill Zima
ICR
Phone: 646 880 9039

Media Relations Contact
Luckin Coffee PR
Email: pr@lkcoffee.com

LIMASSOL, Cyprus, Sept. 29, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced the preliminary results of the previously announced tender offer by the Company to purchase for cash up to $20,000,000 in value of its ordinary shares, no par value per ordinary share (each, a “share”), or up to 1,813,236 shares, at a purchase price of $11.03 per share, net to the seller in cash, without interest, less any applicable withholding taxes, which expired at 5:00 p.m., Eastern Time, on September 28, 2026 (the “Expiration Time”).

Based on the preliminary count by Continental Stock Transfer & Trust Company, the depositary for the tender offer (the “Depositary”), 56,830 shares were properly tendered and not properly withdrawn prior to the Expiration Time, including 280 shares tendered through notice of guaranteed delivery, which may be delivered within the two business days settlement period.

In accordance with the terms and conditions of the tender offer, and based on the preliminary results reported by the Depositary, the Company expects to purchase up to 56,830 shares through the tender offer at a price of $11.03 per share, for an aggregate cost of approximately $626.8 thousand, excluding fees relating to the tender offer. The number of shares that the Company expects to purchase in the tender offer represents approximately 0.3% of the total number of issued ordinary shares of the Company outstanding as of the commencement of the tender offer on August 31, 2026.

The Company expects to have approximately 18.1 million shares outstanding immediately following payment for the shares purchased in the tender offer. The shares acquired pursuant to the tender offer will be held by the Company as treasury shares, and will remain available for the Company to issue in the future.

The number of shares expected to be purchased by the Company is preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the Depositary and is based on the assumption that all shares tendered through notice of guaranteed delivery will be delivered within the two business days settlement period. The final number of shares to be purchased by the Company will be announced following the completion by the Depositary of the confirmation process. Payment for the shares accepted for purchase under the tender offer will occur promptly thereafter.

D.F. King & Co., Inc. is serving as the information agent for the tender offer, and Continental Stock Transfer & Trust Company is serving as the Depositary. For all questions regarding the tender offer, please contact the information agent, D.F. King & Co., Inc., by calling +1 (800) 549-6864, or by emailing gdev@dfking.com.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Certain information regarding the tender offer

The information in this press release describing GDEV Inc.’s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of GDEV Inc. in the tender offer. The tender offer will only be made pursuant to the Offer to Purchase, the related Letter of Transmittal and other related materials filed as part of the Tender Offer Statement on Schedule TO, in each case as may be amended or supplemented from time to time. Shareholders should read such Offer to Purchase and related materials carefully and in their entirety because they contain important information, including the various terms and conditions of the tender offer.

Shareholders of GDEV Inc. may obtain a free copy of the Tender Offer Statement on Schedule TO, the Offer to Purchase and other documents that GDEV Inc. is filing with the Securities and Exchange Commission from the Securities and Exchange Commission’s website at www.sec.gov. Shareholders may also obtain a copy of these documents, without charge, from D.F. King & Co., Inc., the information agent for the tender offer, by calling (800) 549-6864 (U.S. toll‑free), or by emailing gdev@dfking.com. Shareholders are urged to carefully read all of these materials prior to making any decision with respect to the tender offer. Shareholders and investors who have questions or need assistance may call D.F. King & Co., Inc., the information agent for the tender offer, toll free at (800) 549-6864, or may email D.F. King & Co., Inc. at gdev@dfking.com.

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2025 Annual Report on Form 20-F, filed by the Company on March 31, 2026, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –

– Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee –

– In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) –

– No relapses observed for any patient who reached CR or MRD-negativity to-date –

– No neurotoxicity or enterocolitis has been observed to-date –

– NEXICART-2 final readout and BLA submission planned mid-2027 –

– Virtual investor event today Sep 29 at 8:00am ET: https://events.q4inc.com/attendee/484851283/ –

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced positive results of an 89% (40/45) complete response (CR) rate in an interim update across all forty-five NEXICART-2 patients, advancing NXC-201 as a potential best-in-class therapy for AL Amyloidosis. All twenty-five new relapsed/refractory AL Amyloidosis patients are either in complete response (CR) or already minimum residual disease (MRD)-negative.   To-date, all patients achieving MRD-negativity reached CR within one year of treatment.   Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee. In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45). No relapses to date have been observed for any patient who reached CR or MRD-negativity to-date. No neurotoxicity or enterocolitis has been observed to-date.   NEXICART-2 final readout and BLA submission are planned in 2027.

“Today, patients with AL Amyloidosis face years of burdensome, continuous treatment. As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden,” said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma, adding: “We are thrilled with NXC-201’s magnitude of effect across a broad range of relapsed/refractory AL Amyloidosis patients in NEXICART-2.” Gabriel Morris, President of Immix Biopharma, added, “NXC-201’s complete response rate continues to increase over time, even as reported patient counts have now more than doubled.   We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”

Investor Webcast and Conference Call Information
The Company will host a conference call to discuss these data at 8:00 a.m. ET today, Sep 29, 2026. The live webcast can be accessed at https://events.q4inc.com/attendee/484851283/ or under “Events & Presentations” in the Investors section of the company’s website at www.immixbio.com. The webcast will be available for replay on the company website. Analysts who wish to join the teleconference and participate in Q&A should register at the link above.

About NEXICART-2
NEXICART-2 (NCT06097832) is a multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. NEXICART-2 is a 45-patient study.

About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.

The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, statements relating to NEXICART-2 final readout and BLA submission planned in mid-2027; making NXC-201 available to patients at commercial launch, if approved; the size of the AL Amyloidosis market; the potential benefits of our product candidate NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size reaching not being accurate; (ii) the risk that Breakthrough Therapy designation will not expedite the development of NXC-201: (iii) the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201 will not be favorably consistent with the data readouts to date, (iv) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (v) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (vi) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (vii) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (viii) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (ix) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2026 and other periodic or current reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.

A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news.

Sarborg Expands Quantum Computing Patent Portfolio, Applying Quantum Sampling to Disease Biology and Drug Targeting

WILMINGTON, De – September 29, 2026 – Sarborg Limited (“Sarborg” or the “Company“) today announced the filing of comprehensive novel intellectual property (IP) expanding its quantum computing applications into human drug discovery, utilising the expansive problem-solving efficiency of quantum sampling. Sarborg is also in active discussions with a leading global quantum computing company regarding a partnership to advance these dedicated models on market-leading quantum hardware.

Existing quantum computing work in drug discovery focuses on simulating individual molecules, but Sarborg’s novel application applies market-leading quantum computation to disease biology itself: the networks of regulators that switch disease genes on and off. Disease genes are frequently controlled by several regulators acting together, a combinatorial layer that conventional network methods cannot see and that grows rapidly harder to compute at scale. This approach requires the complexity of quantum sampling solutions.

The uniqueness of Sarborg’s intellectual property filing ensures a model that runs on existing classical infrastructure and produces commercially usable output, while being dedicated to maximising the current quantum processing capability and maintaining the full biological complexity of the model. To the Company’s knowledge, no other method combines quantum-ready sampling of disease network structure with a calibrated higher-order screen of this kind.

Applied across 150 disease networks in multiple indications, including Crohn’s disease, chronic obstructive pulmonary disease (COPD) and psoriasis, the model found that combinatorially regulated genes concentrate cell-surface receptors and ion channels, among the most targeted opportunities in pharmacology, and carry independent human genetic support for disease in all three conditions. In COPD, they aligned approximately eightfold with the disease’s own established drug targets, including CHRM3, the target of tiotropium. In a simulation against an exact ground truth, Sarborg’s quantum-enhanced sampler reproduced the model’s results with complete agreement, converging on a complex disease gene for which a matched classical sampler remained trapped.

This novel filing builds on the Company’s July 2026 quantum-enabled PRISM filing in agriculture and extends its patent estate across each layer of its Signature Intelligence models.

“Much of the quantum sector is still looking for problems that genuinely suit the hardware. We started from one,” said Dr. Andrew Regan, Chief Executive Officer of Sarborg. “Disease genes are controlled by committees of regulators acting together, a combinatorial layer conventional methods miss, and quantum samplers are built to explore. Our model delivers druggable, genetically supported targets today and is ready for quantum hardware by design. Our discussions with a leading quantum computing company to implement it in hardware are advancing strongly.”

About Sarborg Limited

Sarborg is an agentic AI and quantum computing signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures using its agentic AI and quantum computing infrastructure, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:
info@sarborg.com
www.sarborg.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com  

• Plug and Arcadia eFuels enter a strategic cooperation agreement positioning Plug as the preferred electrolyzer supplier for more than 1 GW of Arcadia eFuels’ e-SAF projects in Europe and the Americas
• 280 MW of Plug’s GenEco electrolyzers will produce the hydrogen behind Project ENDOR at the Port of Vordingborg, Denmark
• Project ENDOR advances toward final investment decision

SLINGERLANDS, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has signed a 280-megawatt (MW) GenEco electrolyzer supply agreement with Arcadia eFuels for Project ENDOR in Denmark, together with a strategic cooperation agreement covering Arcadia’s future projects. The agreement follows three years of joint engineering work, and deliveries will begin after the project issues notice to proceed.

ENDOR is Arcadia eFuels’ flagship facility, located at the Port of Vordingborg on Denmark’s south coast. Once built, it will use renewable grid power to run 280 MW of Plug electrolyzers, producing roughly 110 tons of renewable hydrogen a day. Arcadia eFuels will combine that hydrogen with captured carbon dioxide to make jet fuel that works in standard aircraft.

The strategic cooperation agreement extends the relationship beyond ENDOR. It positions Plug as the preferred electrolyzer supplier for four additional Arcadia eFuels projects in Europe and the Americas, representing more than 1 GW of potential electrolyzer capacity, along with priority access for Arcadia eFuels to Plug’s manufacturing capacity as each project advances.

“Signing the ENDOR supply agreement alongside a strategic cooperation agreement positions Plug not only as the electrolyzer supplier for Arcadia eFuels’ flagship project, but as their preferred partner across a pipeline of e-SAF developments in Europe and the Americas,” said José Luis Crespo, President and Chief Executive Officer of Plug. “This reflects continued confidence in our GenEco technology, our manufacturing capacity, and Plug’s ability to deliver complex, high-capacity projects at scale. Europe remains our most active electrolyzer market, and e-SAF is one of the fastest-growing segments of demand as aviation fuel mandates take effect. Producing that fuel from European electricity and European carbon rather than imported oil also strengthens the continent’s energy security.”

“Project ENDOR is on the path to final investment decision, and this supply agreement from Plug signifies one of the many project documents that have been finalized,” said Amy Hebert, Chief Executive Officer of Arcadia eFuels. “Sustainable aviation fuel made from renewable hydrogen and captured carbon is what will get aviation to its decarbonization targets, and Plug gives us a proven and bankable electrolyzer partner at the scale this project demands.”

e-SAF is produced from renewable electricity and captured carbon rather than crude oil. The EU’s ReFuelEU Aviation mandate requires a rising share of sustainable aviation fuel at European airports, including a sub-target reserved for synthetic fuels from 2030, which makes projects like ENDOR both a compliance route for airlines and a domestic source of aviation fuel for Europe.

Plug is executing multiple projects with a combined capacity in the multi-gigawatt range across Denmark, the U.K., Spain and Portugal, including the 100 MW GenEco installation at Galp’s Sines refinery. Project ENDOR extends that footprint into e-fuels as aviation fuel mandates take effect.

About Plug Power
Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to customers worldwide across material handling, industrial applications, and energy production, advancing energy independence and decarbonization at scale.

Plug has deployed electrolyzers on five continents, along with more than 76,000 fuel cell systems and 275 fueling stations, and is the world’s largest user of liquid hydrogen. Its expanding generation network produces 40 tons of hydrogen per day, supplying large-scale projects that redefine industrial power for customers globally.

Headquartered in New York, with employees and state-of-the-art manufacturing facilities around the world, Plug powers global leaders like BMW, BP, Walmart, Amazon, and Home Depot.

For more information, visit www.plugpower.com.

About Arcadia eFuels
Arcadia eFuels is committed to building facilities to produce the world’s future fuels. These net-zero carbon fuels will allow the transport sector, namely aviation and shipping, to use fuels directly, without changes to existing engines and infrastructure. Arcadia eFuels aims to produce fuels worldwide to help meet the aviation industry’s decarbonization goals.

Please visit www.arcadiaefuels.com to learn more or contact us at info@arcadiaefuels.com.

Plug Safe Harbor

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts, including, without limitation, statements regarding the expected development, financing, construction, final investment decision (“FID”), operation, timing, capacity, and performance of Project ENDOR; the anticipated supply and deployment of Plug’s GenEco™ electrolyzers; expected renewable hydrogen production volumes; the production, market demand for, and adoption of e-sustainable aviation fuel (“e-SAF”) and other synthetic fuels; the benefits of the strategic cooperation agreement with Arcadia eFuels; Plug’s status as Arcadia eFuels’ preferred electrolyzer supplier; potential future orders, projects, and opportunities associated with Arcadia eFuels’ development pipeline; anticipated regulatory support, mandates, and market conditions for hydrogen and e-fuels; Plug’s growth opportunities in Europe, the Americas, and other markets; and other statements regarding the Company’s future operating results, financial condition, business strategy, performance, prospects, objectives, plans, and opportunities, are forward-looking statements. In addition, certain statements in this press release relating to Arcadia eFuels, Project ENDOR, and Arcadia eFuels’ other projects are based in part on information provided by Arcadia eFuels, or other third parties, which the Company has not independently verified, and the Company assumes no responsibility for the accuracy or completeness of such third-party information. Forward-looking statements can generally, but not always, be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “continue,” “project,” “potential,” “target,” “outlook,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among other things: whether Project ENDOR achieves FID and proceeds to construction and operation; whether Arcadia eFuels’ additional projects in Europe and the Americas advance as currently anticipated; whether any potential future electrolyzer orders or projects materialize under the strategic cooperation agreement; the ability of the parties to satisfy contractual, financing, permitting, regulatory, and technical milestones; the availability and cost of renewable electricity and captured carbon dioxide; whether projected hydrogen production volumes, plant performance metrics, and e-SAF production targets are achieved; the development, economics, competitiveness, and demand for hydrogen, e-SAF, and synthetic fuels; changes in applicable laws, regulations, government incentives, sustainability mandates, and aviation fuel requirements; supply chain constraints, inflationary pressures, and project execution risks; Plug’s ability to manufacture, deliver, install, and service its electrolyzer systems on anticipated schedules; the Company’s ability to manage costs, maintain liquidity, and secure additional financing as needed; and general economic, market, competitive, geopolitical, and regulatory conditions. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Plug’s business generally, see Plug’s public filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of Plug’s Annual Report on Form 10-K for the year ended December 31, 2025, Plug’s subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which are not guarantees of future performance and speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PLUG MEDIA CONTACT
Teal Hoyos
media@plugpower.com